Abstract: Methods for treating obesity are provided and include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Methods for reducing adiposity and adipogenesis are also provided and make use of a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject.

Abstract: Methods for treating obesity are provided and include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Methods for reducing adiposity and adipogenesis are also provided and make use of a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject.

Abstract: Retroviral vectors which encode interferon alpha are disclosed. These canbe used to produce recombinant transduced cells. Both the vectors and the recombinant transduced cells can be used therapeutically. The cells can also be used to produce alpha interferon.

Abstract: A method for treating a high vascular resistance disorder in a mammal by administering to a mammalian organism in need of such treatment a sufficient amount of L-arginine or pharmaceutically acceptable salt thereof to treat a high vascular resistance disorder. The L-arginine is typically administered in the range of about 1 mg to 1500 mg per day. High vascular resistance disorders include hypertension, primary or secondary vasospasm, angina pectoris, cerebral ischemia and preeclampsia. Also disclosed is a method for preventing or treating bronchial asthma in a mammal by administering to a mammalian organism in need of such prevention or treatment a sufficient amount of L-arginine to prevent or treat bronchial asthma.

Abstract: The invention relates to a method for treating or preventing ocular swelling and corneal-conjunctival inflammation. This is accomplished by administering to the eye of a subject, either before or after exposure to an ocular swelling stimulus, an amount of a heme oxygenase inducing agent sufficient to increase levels of heme oxygenase in the eye and thereby to reduce or to regulate the amount of 12(R) hydroxyeicosatetraenoic and 12(R) DiHETE acids present. Particularly preferred agents include stannous compounds, such as SnCl.sub.2, other metals, heme derivatives and Vitamin B12. These compounds may be administered in various forms.